Whether you are an academic lab, a one-person biotechnology company, a research insititute, or large pharma, agricultural, or biofuels company, we're here to help you with the latest and best bioinformatics technologies to advance your research.
We have 15 years of biotech and major pharma experience with computational biology analyses on gene expression, next generation sequencing, and other large-scale data and with bioinformatic infrastructure development. We can provide gene ranking, target identification, biomarker identification, pathway analysis, and much more - all to help you understand your data the best way possible.
We provide guidance based on years of biotech and pharma experience to ensure that your experiments are using the best and most appropriate technology to answer your scientific questions and are powered to provide maximal impact.
In addition to the standard GSEA and the Broad GSEA, we have developed a semi-quantitative method that provides an estimate of how much cellular processes increase or decrease between expression datasets.
We use a multiple parameter optimisation method that ranks genes based on their response across disparate data types and is tolerant of missing data. The top-ranked genes are then analysed with pathway and functional analyses. This method has been successfully applied to multiple therapeutic areas and will be showcased at the Society for Neuroscience meeting, Nov. 2011.
Whether you need standard sequence comparisons and motif hunting, or assembly and calculating expression levels from your Illumina or 454 Next Gen Sequencing data, we have the capability to handle it. We leverage Amazon's compute cloud to obtain scalability thus reducing your overhead and costs.
We are the leaders in using Ariadne's Pathway Studio and Ingenuity's Pathway Analysis to build de novo pathways based on causal inferencing on expression and high-throughput screening data.
DKP Genomics has not received any reviews.
DKP Genomics has not received any endorsements.